BCAB - BioAtla, Inc.

4.59
-0.320   -6.972%

Share volume: 27,975
Last Updated: 04-17-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$4.91
-0.32
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 40%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.49%
1 Month
2,836.66%
3 Months
1,331.69%
6 Months
647.56%
1 Year
1,254.38%
2 Year
118.05%
Key data
Stock price
$4.59
P/E Ratio 
0.00
DAY RANGE
$4.56 - $4.91
EPS 
-$1.05
52 WEEK RANGE
$0.12 - $6.52
52 WEEK CHANGE
$1,254.38
MARKET CAP 
40.395 M
YIELD 
N/A
SHARES OUTSTANDING 
58.792 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,759
AVERAGE 30 VOLUME 
$671,223
Company detail
CEO: Jay M. Short
Region: US
Website: bioatla.com
Employees: 60
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate.

Recent news